Bengaluru, India, 21 September 2026: Biomoneta Research has announced the launch of Avata Air, an indoor air-purification and microbial decontamination device, in collaboration with Panasonic. The product is now available through Panasonic’s MirAIe Lifestyle platform, marking Biomoneta’s entry into the Indian consumer air-care market. Unlike conventional air purifiers that primarily focus on dust, smoke and particulate matter, Avata Air has been designed to address both common airborne pollutants and invisible biological contaminants present in indoor environments.
At the heart of the device is Biomoneta’s patented ZeBox technology, which uses a non-ionising electric field and a microbicidal surface to capture and inactivate airborne microorganisms. According to the company, the device eliminates more than 99.999 % of airborne microorganisms while removing 99.97 % of airborne particles and harmful gases.
“Avata Air represents an important milestone in Biomoneta’s journey,” said Arindam Ghatak, Co-founder and Chief Executive Officer of Biomoneta Research. “For more than a decade, we have worked to understand how airborne microorganisms can be captured and eliminated safely in occupied spaces. Through this collaboration with Panasonic, we can now bring the same core technology developed for demanding healthcare environments into Indian homes.”
From healthcare environments to Indian homes
Biomoneta’s microbial air-decontamination technology has previously been deployed and evaluated in healthcare environments, including intensive care units, operating theatres, IVF facilities and neonatal care facilities. The company’s medical-grade product, Avata Rx, received clearance from the United States Food and Drug Administration as a Class II medical device. Avata Air is a separate consumer product, but incorporates the same underlying ZeBox technology used in the US FDA-cleared Avata Rx platform.
“What began as a scientific effort to solve a serious infection-control problem has now evolved into a platform with applications across hospitals, homes and other shared spaces,” Ghatak said. “Our objective is not simply to introduce another air purifier. We want to make protection from airborne microorganisms practical, measurable and accessible to families.”
.jpg)
